Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system

British Journal of Pharmacology

Volumn 163, Issue 6, 2011, Pages 1140-1162

  Schuchardt, Mirjam ^a,b   Tölle, Markus ^a   Prüfer, Jasmin ^a,b   Van Der Giet, Markus ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Department of Nephrology ^*  (Germany)

Author keywords

atherogenesis; endothelial cell; FTY720; inflammation; lipoproteins; permeability; sphingosine 1 phosphate; vascular smooth muscle cell; vascular tone

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; 3 [2 (3 TRIFLUOROMETHYL 4 BIPHENYLYL)BENZO[B]THIEN 5 YLMETHYLAMINO]PROPIONIC ACID; 4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; COMPOUND 5; CYCLOSPORIN; CYM 5442; FINGOLIMOD; LT 1002; LT 1009; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PONESIMOD; SONEPCIZUMAB; SPHINGOMAB; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE INHIBITOR; TY 52156; UNCLASSIFIED DRUG; VASOACTIVE AGENT; VPC 23153; VPC 24191; W 146;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; BLOOD VESSEL TONE; BRADYCARDIA; CARDIAC GRAFT REJECTION; CARDIOVASCULAR SYSTEM; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; INFLAMMATION; INTRACELLULAR SIGNALING; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; LEUKOCYTE ADHERENCE; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; HUMANS; LYSOPHOSPHOLIPIDS; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 79959686782     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01260.x     Document Type: Review

References (284)

1. Alderton F, Rakhit S, Kong KC, Palmer T, Sambi B, Pyne S, et al,. (2001). Tethering of the platelet-derived growth factor beta receptor to G-protein-coupled receptors. A novel platform for integrative signaling by these receptor classes in mammalian cells. J Biol Chem 276: 28578-28585. (Pubitemid 37391573)
2. Alewijnse AE, Peters SL, (2008). Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol 585: 292-302.
3. Alewijnse AE, Peters SL, Michel MC, (2004). Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol 143: 666-684. (Pubitemid 39611603)
4. Allende ML, Proia RL, (2002). Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta 1582: 222-227. (Pubitemid 34634133)
5. Allende ML, Yamashita T, Proia RL, (2003). G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102: 3665-3667. (Pubitemid 37409386)
6. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, et al,. (2004). Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 279: 52487-52492. (Pubitemid 39656625)
7. An S, Zheng Y, Bleu T, (2000). Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5. J Biol Chem 275: 288-296. (Pubitemid 30038984)
8. Anelli V, Gault CR, Snider AJ, Obeid LM, (2010). Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro. FASEB J 24: 2727-2738.
9. Argraves KM, Argraves WS, (2007). HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 48: 2325-2333. (Pubitemid 350058744)
10. Argraves KM, Wilkerson BA, Argraves WS, Fleming PA, Obeid LM, Drake CJ, (2004). Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis. J Biol Chem 279: 50580-50590. (Pubitemid 39577875)
11. Auge N, Nikolova-Karakashian M, Carpentier S, Parthasarathy S, Negre-Salvayre A, Salvayre R, et al,. (1999). Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J Biol Chem 274: 21533-21538.
12. Auge N, Negre-Salvayre A, Salvayre R, Levade T, (2000). Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog Lipid Res 39: 207-229. (Pubitemid 30224704)
13. Awad AS, Ye H, Huang L, Li L, Foss FW, Jr, Macdonald TL, et al,. (2006). Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 290: F1516-F1524. (Pubitemid 43830779)
14. Bajwa A, Jo S-K, Ye H, Huang L, Dondeti KR, Rosin DL, et al,. (2010). Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol 21: 955-965.
15. Balthasar S, Bergelin N, Lof C, Vainio M, Andersson S, Tornquist K, (2008). Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells. Endocr Relat Cancer 15: 521-534. (Pubitemid 351880840)
16. Baudhuin LM, Jiang Y, Zaslavsky A, Ishii I, Chun J, Xu Y, (2004). S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). FASEB J 18: 341-343.
17. Baumruker T, Billich A, Brinkmann V, (2007). FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs 16: 283-289. (Pubitemid 46394853)
18. Bergelin N, Lof C, Balthasar S, Kalhori V, Tornquist K, (2010). S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology 151: 2994-3005.
19. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al,. (1995). Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91: 2488-2496.
20. Birgbauer E, Chun J, (2006). New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 63: 2695-2701. (Pubitemid 44913311)
21. Bischoff A, Czyborra P, Meyer Zu Heringdorf D, Jakobs KH, Michel MC, (2000). Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol 130: 1878-1883. (Pubitemid 30655800)
22. Bode C, Sensken SC, Peest U, Beutel G, Thol F, Levkau B, et al,. (2010). Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem 109: 1232-1243.
23. Boguslawski G, Grogg JR, Welch Z, Ciechanowicz S, Sliva D, Kovala AT, et al,. (2002). Migration of vascular smooth muscle cells induced by sphingosine 1-phosphate and related lipids: potential role in the angiogenic response. Exp Cell Res 274: 264-274.
24. Bolick DT, Srinivasan S, Kim KW, Hatley ME, Clemens JJ, Whetzel A, et al,. (2005). Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol 25: 976-981. (Pubitemid 40627842)
25. Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, et al,. (2010). 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 53: 4198-4211.
26. Bolz SS, Vogel L, Sollinger D, Derwand R, Boer C, Pitson SM, et al,. (2003). Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation 108: 342-347. (Pubitemid 36899027)
27. Bornfeldt KE, Graves LM, Raines EW, Igarashi Y, Wayman G, Yamamura S, et al,. (1995). Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction. J Cell Biol 130: 193-206.
28. Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, et al,. (2010). Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J 31: 67-76.
29. Brindley DN, (2004). Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J Cell Biochem 92: 900-912. (Pubitemid 44264240)
30. Brinkmann V, (2007). Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84-105. (Pubitemid 46990553)
31. Brinkmann V, Wilt C, Kristofic C, Nikolova Z, Hof RP, Chen S, et al,. (2001). FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant Proc 33: 3078-3080. (Pubitemid 34042491)
32. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al,. (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457. (Pubitemid 34952287)
33. Brinkmann V, Cyster JG, Hla T, (2004). FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4: 1019-1025. (Pubitemid 38868590)
34. Brossard P, Hofmann S, Cavallaro M, Halabi A, Dingemanse J, (2009). Entry-into-humans study with ACT-128800, a selective S1P1 receptor agonist: tolerability, safety, pharmacokinetics, and pharmacodynamics. In: Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics. Washington, DC, pp. S63-S64.
35. Brown M, Adyshev D, Bindokas V, Moitra J, Garcia JG, Dudek SM, (2010). Quantitative distribution and colocalization of non-muscle myosin light chain kinase isoforms and cortactin in human lung endothelium. Microvasc Res 80: 75-88.
36. Budde K, Schmouder RL, Nashan B, Brunkhorst R, Lücker PW, Mayer T, et al,. (2003). Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 3: 846-854. (Pubitemid 36827906)
37. Butler J, Lana D, Round O, LaMontagne K, (2004). Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells. Prostaglandins Other Lipid Mediat 73: 29-45. (Pubitemid 38446469)
38. Caballero S, Swaney J, Moreno K, Afzal A, Kielczewski J, Stoller G, et al,. (2009). Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res 88: 367-377.
39. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, et al,. (2002). International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54: 265-269. (Pubitemid 34575716)
40. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, et al,. (2010). Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 16: 197-207.
41. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al,. (1996). Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800-803. (Pubitemid 26243122)
42. Cuvillier O, Rosenthal DS, Smulson ME, Spiegel S, (1998). Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes. J Biol Chem 273: 2910-2916. (Pubitemid 28133941)
43. Damirin A, Tomura H, Komachi M, Liu JP, Mogi C, Tobo M, et al,. (2007). Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol 292: H2513-H2522. (Pubitemid 47084636)
44. Daum G, Grabski A, Reidy MA, (2009). Sphingosine 1-phosphate: a regulator of arterial lesions. Arterioscler Thromb Vasc Biol 29: 1439-1443.
45. Davis MD, Clemens JJ, Macdonald TL, Lynch KR, (2005). Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 280: 9833-9841. (Pubitemid 40395829)
46. De Palma C, Meacci E, Perrotta C, Bruni P, Clementi E, (2006). Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vasc Biol 26: 99-105. (Pubitemid 43732234)
47. Delbridge MS, Shrestha BM, Raftery AT, El Nahas AM, Haylor J, (2007a). FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury. Transplant Proc 39: 2992-2996. (Pubitemid 350251451)
48. Delbridge MS, Shrestha BM, Raftery AT, El Nahas AM, Haylor JL, (2007b). Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine. Transplantation 84: 187-195. (Pubitemid 47205752)
49. Diab KJ, Adamowicz JJ, Kamocki K, Rush NI, Garrison J, Gu Y, et al,. (2010). Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema. Am J Respir Crit Care Med 181: 344-352.
50. Donati C, Cencetti F, Nincheri P, Bernacchioni C, Brunelli S, Clementi E, et al,. (2007). Sphingosine 1-phosphate mediates proliferation and survival of mesoangioblasts. Stem Cells 25: 1713-1719. (Pubitemid 47121849)
51. Duenas AI, Aceves M, Fernandez-Pisonero I, Gomez C, Orduna A, Crespo MS, et al,. (2008). Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate. Cardiovasc Res 79: 537-544.
52. Egom EEA, Ke Y, Musa H, Mohamed TMA, Wang T, Cartwright E, et al,. (2010). FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol 48: 406-414.
53. Feistritzer C, Riewald M, (2005). Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105: 3178-3184.
54. Foss FW, Jr, Snyder AH, Davis MD, Rouse M, Okusa MD, Lynch KR, et al,. (2007). Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem 15: 663-677. (Pubitemid 44880732)
55. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, et al,. (2007). Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469-475.
56. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al,. (2003). Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63: 5962-5969. (Pubitemid 37187498)
57. Fujishiro J, Kudou S, Iwai S, Takahashi M, Hakamata Y, Kinoshita M, et al,. (2006a). Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation 82: 804-812. (Pubitemid 44472474)
58. Fujishiro J, Suzuki C, Kudou S, Yasue T, Hakamata Y, Takahashi M, et al,. (2006b). Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats. J Heart Lung Transplant 25: 825-833. (Pubitemid 43963378)
59. Futerman AH, Riezman H, (2005). The ins and outs of sphingolipid synthesis. Trends Cell Biol 15: 312-318. (Pubitemid 40805327)
60. Fyrst H, Saba JD, (2010). An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 6: 489-497.
61. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, et al,. (2001). Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108: 689-701. (Pubitemid 32906197)
62. Gardell SE, Dubin AE, Chun J, (2006). Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 12: 65-75. (Pubitemid 43202124)
63. Goetzl EJ, Kong Y, Mei B, (1999). Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 162: 2049-2056. (Pubitemid 29288824)
64. Goetzl EJ, Wang W, McGiffert C, Huang MC, Graler MH, (2004). Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system. J Cell Biochem 92: 1104-1114. (Pubitemid 44264222)
65. Gon Y, Wood MR, Kiosses WB, Jo E, Sanna MG, Chun J, et al,. (2005). S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc Natl Acad Sci USA 102: 9270-9275. (Pubitemid 40923553)
66. Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, Marsolais D, et al,. (2008). Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 74: 1308-1318.
67. Goparaju SK, Jolly PS, Watterson KR, Bektas M, Alvarez S, Sarkar S, et al,. (2005). The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol Cell Biol 25: 4237-4249. (Pubitemid 40617669)
68. Gottlieb D, Heideman W, Saba JD, (1999). The DPL1 gene is involved in mediating the response to nutrient deprivation in Saccharomyces cerevisiae. Mol Cell Biol Res Commun 1: 66-71. (Pubitemid 129532295)
69. Graler MH, (2010). Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions. Cell Physiol Biochem 26: 79-86.
70. Graler MH, Goetzl EJ, (2004). The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18: 551-553.
71. Hanafusa N, Yatomi Y, Yamada K, Hori Y, Nangaku M, Okuda T, et al,. (2002). Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. Nephrol Dial Transplant 17: 580-586. (Pubitemid 34308811)
72. Hanel P, Andreani P, Graler MH, (2007). Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 21: 1202-1209. (Pubitemid 46495709)
73. Hannun YA, Obeid LM, (2008). Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev 9: 139-150. (Pubitemid 351158911)
74. Hayashi T, Noshita N, Sugawara T, Chan PH, (2003). Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J Cereb Blood Flow Metab 23: 166-180. (Pubitemid 36188455)
75. Hedemann J, Fetscher C, Michel MC, (2004). Comparison of noradrenaline and lysosphingolipid-induced vasoconstriction in mouse and rat small mesenteric arteries. Auton Autacoid Pharmacol 24: 77-85. (Pubitemid 39536639)
76. Hemmings DG, (2006). Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine. Naunyn Schmiedebergs Arch Pharmacol 373: 18-29.
77. Hemmings DG, Xu Y, Davidge ST, (2004). Sphingosine 1-phosphate-induced vasoconstriction is elevated in mesenteric resistance arteries from aged female rats. Br J Pharmacol 143: 276-284. (Pubitemid 39315148)
78. Herr DR, Grillet N, Schwander M, Rivera R, Muller U, Chun J, (2007). Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. J Neurosci 27: 1474-1478.
79. Herzinger T, Kleuser B, Schafer-Korting M, Korting HC, (2007). Sphingosine-1-phosphate signaling and the skin. Am J Clin Dermatol 8: 329-336. (Pubitemid 350174535)
80. Hla T, (2004). Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 15: 513-520. (Pubitemid 38953947)
81. Hla T, Venkataraman K, Michaud J, (2008). The vascular S1P gradient-cellular sources and biological significance. Biochim Biophys Acta 1781: 477-482.
82. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, Caron MG, et al,. (2001). Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291: 1800-1803. (Pubitemid 32198987)
83. Hofmann U, Burkard N, Vogt C, Thoma A, Frantz S, Ertl G, et al,. (2009). Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. Cardiovasc Res 83: 285-293.
84. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, et al,. (2008). FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 68: 1204-1212. (Pubitemid 351272240)
85. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, et al,. (1999). FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 100: 1322-1329. (Pubitemid 29440126)
86. Igarashi J, Michel T, (2001). Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways. J Biol Chem 276: 36281-36288.
87. Igarashi J, Michel T, (2009). Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc Res 82: 212-220.
88. Igarashi J, Erwin PA, Dantas AP, Chen H, Michel T, (2003). VEGF induces S1P1 receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors. Proc Natl Acad Sci USA 100: 10664-10669. (Pubitemid 37140085)
89. Igarashi J, Shoji K, Hashimoto T, Moriue T, Yoneda K, Takamura T, et al,. (2009). Transforming growth factor-beta1 downregulates caveolin-1 expression and enhances sphingosine 1-phosphate signaling in cultured vascular endothelial cells. Am J Physiol 297: C1263-C1274.
90. Ikeda M, Kihara A, Igarashi Y, (2004). Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-resident, integral membrane protein with the pyridoxal 5′-phosphate binding domain exposed to the cytosol. Biochem Biophys Res Commun 325: 338-343. (Pubitemid 39441198)
91. Im D-S, (2010). Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin 31: 1213-1222.
92. Inoue S, Nakazawa T, Cho A, Dastvan F, Shilling D, Daum G, et al,. (2007). Regulation of arterial lesions in mice depends on differential smooth muscle cell migration: a role for sphingosine-1-phosphate receptors. J Vasc Surg 46: 756-763. (Pubitemid 47446118)
93. Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, Contos JJ, et al,. (2001). Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem 276: 33697-33704.
94. Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, et al,. (2005). Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 25: 1459-1469. (Pubitemid 40250722)
95. Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne DA, et al,. (2005). S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 12: 703-715. (Pubitemid 43142048)
96. Johnson KR, Johnson KY, Becker KP, Bielawski J, Mao C, Obeid LM, (2003). Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability. J Biol Chem 278: 34541-34547. (Pubitemid 37553303)
97. Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, et al,. (2003). Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 76: 1079-1084. (Pubitemid 37280837)
98. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al,. (2006). Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124-1140. (Pubitemid 44394919)
99. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al,. (2010). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401.
100. Kawanabe T, Kawakami T, Yatomi Y, Shimada S, Soma Y, (2007). Sphingosine 1-phosphate accelerates wound healing in diabetic mice. J Dermatol Sci 48: 53-60. (Pubitemid 47284808)
101. Kawasaki H, Ozawa K, Yamamoto K, (2001). Pyrazolopyridine compounds and use thereof as drugs. WO0198301.
102. Kawata T, Ishizuka T, Tomura H, Hisada T, Dobashi K, Tsukagoshi H, et al,. (2005). Sphingosine 1-phosphate inhibits migration and RANTES production in human bronchial smooth muscle cells. Biochem Biophys Res Commun 331: 640-647. (Pubitemid 40602682)
103. Keul P, Tolle M, Lucke S, Lipinski K, Heusch G, Schuchardt M, et al,. (2007). The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27: 607-613.
104. Kharel Y, Lee S, Snyder AH, Sheasley-O'neill SL, Morris MA, Setiady Y, et al,. (2005). Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 280: 36865-36872. (Pubitemid 41587768)
105. Kihara A, Igarashi Y, (2008). Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta 1781: 496-502.
106. Kimura T, Watanabe T, Sato K, Kon J, Tomura H, Tamama K, et al,. (2000). Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 348 Pt 1: 71-76. (Pubitemid 30312132)
107. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, et al,. (2001). Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 276: 31780-31785.
108. Kimura T, Hasegawa T, Nakai H, Azuma T, Usui N, Sasaki T, et al,. (2003). FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells. Transplantation 75: 1469-1474. (Pubitemid 36597280)
109. Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, Ishizuka T, et al,. (2006a). Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 281: 37457-37467. (Pubitemid 46042049)
110. Kimura T, Tomura H, Mogi C, Kuwabara A, Ishiwara M, Shibasawa K, et al,. (2006b). Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell Signal 18: 841-850. (Pubitemid 43208937)
111. Klingenberg R, Nofer JR, Rudling M, Bea F, Blessing E, Preusch M, et al,. (2007). Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27: 2392-2399. (Pubitemid 350203955)
112. Kluk MJ, Hla T, (2001). Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res 89: 496-502. (Pubitemid 34132643)
113. Kluk MJ, Hla T, (2002). Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta 1582: 72-80. (Pubitemid 34634113)
114. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, et al,. (2004). The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 279: 29367-29373. (Pubitemid 38915815)
115. Kono M, Belyantseva IA, Skoura A, Frolenkov GI, Starost MF, Dreier JL, et al,. (2007). Deafness and stria vascularis defects in S1P2 receptor-null mice. J Biol Chem 282: 10690-10696. (Pubitemid 47093459)
116. Krump-Konvalinkova V, Yasuda S, Rubic T, Makarova N, Mages J, Erl W, et al,. (2005). Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. Arterioscler Thromb Vasc Biol 25: 546-552. (Pubitemid 40315676)
117. Krump-Konvalinkova V, Chwalla I, Siess W, (2008). FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression. Biochem Biophys Res Commun 370: 603-608.
118. Kwon YG, Min JK, Kim KM, Lee DJ, Billiar TR, Kim YM, (2001). Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production. J Biol Chem 276: 10627-10633. (Pubitemid 38089231)
119. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, et al,. (2006). Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66: 221-231. (Pubitemid 43166028)
120. Langlois S, Gingras D, Beliveau R, (2004). Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 103: 3020-3028. (Pubitemid 38451675)
121. Laychock SG, Sessanna SM, Lin MH, Mastrandrea LD, (2006). Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet beta-cells. Endocrinology 147: 4705-4712. (Pubitemid 44402178)
122. Le Stunff H, Peterson C, Liu H, Milstien S, Spiegel S, (2002). Sphingosine-1-phosphate and lipid phosphohydrolases. Biochim Biophys Acta 1582: 8-17. (Pubitemid 34634106)
123. Lee H, Lin CI, Liao JJ, Lee YW, Yang HY, Lee CY, et al,. (2004). Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-kappaB-dependent mechanism. Am J Physiol Cell Physiol 287: C1657-C1666. (Pubitemid 39507683)
124. Lee JF, Zeng Q, Ozaki H, Wang L, Hand AR, Hla T, et al,. (2006). Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem 281: 29190-29200. (Pubitemid 44507063)
125. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, et al,. (1998). Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279: 1552-1555. (Pubitemid 28217081)
126. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al,. (1999). Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99: 301-312. (Pubitemid 29519909)
127. Lien YH, Yong KC, Cho C, Igarashi S, Lai LW, (2006). S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int 69: 1601-1608.
128. Limaye V, (2008). The role of sphingosine kinase and sphingosine-1- phosphate in the regulation of endothelial cell biology. Endothelium 15: 101-112. (Pubitemid 351891374)
129. Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA, et al,. (2005). Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 105: 3169-3177.
130. Limaye V, Vadas MA, Pitson SM, Gamble JR, (2009). The effects of markedly raised intracellular sphingosine kinase-1 activity in endothelial cells. Cell Mol Biol Lett 14: 411-423.
131. Lin DA, Boyce JA, (2006). Lysophospholipids as mediators of immunity. Adv Immunol 89: 141-167.
132. Lin CI, Chen CN, Chen JH, Lee H, (2006). Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J Cell Biochem 99: 1216-1232. (Pubitemid 44673976)
133. Lin CI, Chen CN, Lin PW, Lee H, (2007). Sphingosine 1-phosphate regulates
134. Liu F, Verin AD, Wang P, Day R, Wersto RP, Chrest FJ, et al,. (2001). Differential regulation of sphingosine-1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity. Am J Respir Cell Mol Biol 24: 711-719. (Pubitemid 32550593)
135. Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S, (2002). Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol 71: 493-511.
136. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al,. (2000). Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951-961.
137. Lorenz JN, Arend LJ, Robitz R, Paul RJ, MacLennan AJ, (2007). Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am J Physiol Regul Integr Comp Physiol 292: R440-R446. (Pubitemid 46089859)
138. Lorquet S, Berndt S, Blacher S, Gengoux E, Peulen O, Maquoi E, et al,. (2010). Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment. FASEB J 24: 3782-3795.
139. Lucke S, Levkau B, (2010). Endothelial functions of sphingosine-1- phosphate. Cell Physiol Biochem 26: 87-96.
140. MacLennan AJ, Carney PR, Zhu WJ, Chaves AH, Garcia J, Grimes JR, et al,. (2001). An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci 14: 203-209. (Pubitemid 32777628)
141. McVerry BJ, Garcia JG, (2004). Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem 92: 1075-1085. (Pubitemid 44264219)
142. McVerry BJ, Garcia JG, (2005). In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal 17: 131-139. (Pubitemid 39371042)
143. Mair K, Robinson E, Kane K, Pyne S, Brett R, Pyne N, et al,. (2010). Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br J Pharmacol 161: 176-192.
144. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al,. (2002). Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349. (Pubitemid 34303689)
145. Marsolais D, Rosen H, (2009). Chemical modulators of sphingosine-1- phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 8: 297-307.
146. Mathews TP, Kennedy AJ, Kharel Y, Kennedy PC, Nicoara O, Sunkara M, et al,. (2010). Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem 53: 2766-2778.
147. Matsuda S, Minowa A, Suzuki S, Koyasu S, (1999). Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J Immunol 162: 3321-3326. (Pubitemid 29313580)
148. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calmels T, (2002). Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 50: 661-670.
149. Means CK, Brown JH, (2009). Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 82: 193-200.
150. Mehta D, Konstantoulaki M, Ahmmed GU, Malik AB, (2005). Sphingosine 1-phosphate-induced mobilization of intracellular Ca2+ mediates rac activation and adherens junction assembly in endothelial cells. J Biol Chem 280: 17320-17328. (Pubitemid 41389201)
151. Merrill AH, Jr, Hannun YA, Bell RM, (1993). Introduction: sphingolipids and their metabolites in cell regulation. Adv Lipid Res 25: 1-24.
152. Michaud J, Im DS, Hla T, (2010). Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol 184: 1475-1483.
153. Michel MC, Mulders AC, Jongsma M, Alewijnse AE, Peters SL, (2007). Vascular effects of sphingolipids. Acta Paediatr Suppl 96: 44-48. (Pubitemid 46481118)
154. Milara J, Mata M, Mauricio MD, Donet E, Morcillo EJ, Cortijo J, (2009). Sphingosine-1-phosphate increases human alveolar epithelial IL-8 secretion, proliferation and neutrophil chemotaxis. Eur J Pharmacol 609: 132-139.
155. Miron VE, Schubart A, Antel JP, (2008). Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 274: 13-17.
156. Miura Y, Yatomi Y, Ohmori T, Osada M, Ozaki Y, (2004). Independence of tumor necrosis factor-alpha-induced adhesion molecule expression from sphingosine 1-phosphate signaling in vascular endothelial cells. J Thromb Haemost 2: 1019-1021. (Pubitemid 40185757)
157. Morishige J, Urikura M, Takagi H, Hirano K, Koike T, Tanaka T, et al,. (2010). A clean-up technology for the simultaneous determination of lysophosphatidic acid and sphingosine-1-phosphate by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using a phosphate-capture molecule, Phos-tag. Rapid Commun Mass Spectrom 24: 1075-1084.
158. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, et al,. (2000). Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 6: 1109-1114.
159. Moriue T, Igarashi J, Yoneda K, Nakai K, Kosaka H, Kubota Y, (2008). Sphingosine 1-phosphate attenuates H2O2-induced apoptosis in endothelial cells. Biochem Biophys Res Commun 368: 852-857.
160. Mulders AC, Mathy MJ, Meyer zu Heringdorf D, ter Braak M, Hajji N, Olthof DC, et al,. (2009). Activation of sphingosine kinase by muscarinic receptors enhances NO-mediated and attenuates EDHF-mediated vasorelaxation. Basic Res Cardiol 104: 50-59.
161. Murakami A, Takasugi H, Ohnuma S, Koide Y, Sakurai A, Takeda S, et al,. (2010). Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol Pharmacol 77: 704-713.
162. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, et al,. (2000). Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 352 Pt 3: 809-815. (Pubitemid 32015038)
163. Nieuwenhuis B, Luth A, Chun J, Huwiler A, Pfeilschifter J, Schafer-Korting M, et al,. (2009). Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P(3) in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone. J Mol Med 87: 645-657.
164. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, et al,. (2001). Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276: 34480-34485.
165. Nofer JR, Geigenmuller S, Gopfert C, Assmann G, Buddecke E, Schmidt A, (2003). High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem Biophys Res Commun 310: 98-103. (Pubitemid 37162768)
166. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, et al,. (2004). HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113: 569-581. (Pubitemid 38542506)
167. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, et al,. (2007). FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115: 501-508. (Pubitemid 46188244)
168. Norata GD, Catapano AL, (2005). Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc Health Risk Manag 1: 119-129.
169. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, et al,. (2008). Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28: 925-931. (Pubitemid 351544109)
170. O'Brien N, Jones ST, Williams DG, Cunningham HB, Moreno K, Visentin B, et al,. (2009). Production and characterization of monoclonal anti-sphingosine-1- phosphate antibodies. J Lipid Res 50: 2245-2257.
171. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, et al,. (2009). Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72: 73-79.
172. Ohmori T, Yatomi Y, Osada M, Kazama F, Takafuta T, Ikeda H, et al,. (2003). Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res 58: 170-177. (Pubitemid 36351635)
173. Okajima F, (2002). Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta 1582: 132-137. (Pubitemid 34634121)
174. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, et al,. (1999). Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 147: 545-558.
175. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, et al,. (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282: 9082-9089. (Pubitemid 47093504)
176. Osada M, Yatomi Y, Ohmori T, Ikeda H, Ozaki Y, (2002). Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun 299: 483-487. (Pubitemid 35365655)
177. Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D, et al,. (2006). A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 13: 1227-1234. (Pubitemid 44762192)
178. Panetti TS, Nowlen J, Mosher DF, (2000). Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration. Arterioscler Thromb Vasc Biol 20: 1013-1019. (Pubitemid 30207575)
179. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al,. (2007). Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316: 295-298. (Pubitemid 46633109)
180. Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, et al,. (2007). The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 109: 1077-1085. (Pubitemid 46220654)
181. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H, et al,. (2004). Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 169: 1245-1251. (Pubitemid 38680403)
182. Peter BF, Lidington D, Harada A, Bolz HJ, Vogel L, Heximer S, et al,. (2008). Role of sphingosine-1-phosphate phosphohydrolase 1 in the regulation of resistance artery tone. Circ Res 103: 315-324.
183. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, et al,. (2003). The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 17: 1411-1421. (Pubitemid 36939148)
184. Peyruchaud O, (2009). Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer. Anticancer Agents Med Chem 9: 381-391.
185. Pham TH, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, et al,. (2010). Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med 207: 17-27.
186. Pitson SM, (2011). Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 36: 97-107.
187. Potteck H, Nieuwenhuis B, Luth A, van der Giet M, Kleuser B, (2010). Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation. Cell Physiol Biochem 26: 67-78.
188. Pyne S, Pyne NJ, (2000). Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 349 (Pt 2): 385-402. (Pubitemid 30465772)
189. Qi X, Okamoto Y, Murakawa T, Wang F, Oyama O, Ohkawa R, et al,. (2010). Sustained delivery of sphingosine-1-phosphate using poly(lactic-co-glycolic acid)-based microparticles stimulates Akt/ERK-eNOS mediated angiogenesis and vascular maturation restoring blood flow in ischemic limbs of mice. Eur J Pharmacol 634: 121-131.
190. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH, (2004). G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 92: 949-966. (Pubitemid 44264244)
191. Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT, et al,. (1999). Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab Invest 79: 1227-1235. (Pubitemid 29489447)
192. Rosen H, Sanna MG, Cahalan SM, Gonzalez-Cabrera PJ, (2007). Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol 28: 102-107. (Pubitemid 46283694)
193. Rosen H, Gonzalez-Cabrera P, Marsolais D, Cahalan S, Don AS, Sanna MG, (2008). Modulating tone: the overture of S1P receptor immunotherapeutics. Immunol Rev 223: 221-235. (Pubitemid 351986190)
194. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S, (2009). Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78: 743-768.
195. Rosenfeldt HM, Hobson JP, Maceyka M, Olivera A, Nava VE, Milstien S, et al,. (2001). EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. FASEB J 15: 2649-2659. (Pubitemid 33131091)
196. Rossig L, Dimmeler S, Zeiher AM, (2001). Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol 96: 11-22. (Pubitemid 32117760)
197. Roviezzo F, Bucci M, Delisle C, Brancaleone V, Di Lorenzo A, Mayo IP, et al,. (2006). Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation. FASEB J 20: 340-342. (Pubitemid 46671164)
198. Ruf W, Furlan-Freguia C, Niessen F, (2009). Vascular and dendritic cell coagulation signaling in sepsis progression. J Thromb Haemost 7 (Suppl. 1): 118-121.
199. Ryu Y, Takuwa N, Sugimoto N, Sakurada S, Usui S, Okamoto H, et al,. (2002). Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res 90: 325-332. (Pubitemid 34633934)
200. Saba JD, Hla T, (2004). Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 94: 724-734. (Pubitemid 38451733)
201. Sachinidis A, Kettenhofen R, Seewald S, Gouni-Berthold I, Schmitz U, Seul C, et al,. (1999). Evidence that lipoproteins are carriers of bioactive factors. Arterioscler Thromb Vasc Biol 19: 2412-2421. (Pubitemid 29477843)
202. Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA, et al,. (2003). S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol 469: 125-134. (Pubitemid 36629558)
203. Salomone S, Potts EM, Tyndall S, Ip PC, Chun J, Brinkmann V, et al,. (2008). Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br J Pharmacol 153: 140-147.
204. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, et al,. (2006). FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 6: 2912-2921.
205. Sanchez T, Hla T, (2004). Structural and functional characteristics of S1P receptors. J Cell Biochem 92: 913-922. (Pubitemid 44264241)
206. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, et al,. (2003). Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 278: 47281-47290. (Pubitemid 37452317)
207. Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T, (2007). Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol 27: 1312-1318. (Pubitemid 46809419)
208. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, et al,. (2004). Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279: 13839-13848. (Pubitemid 38468916)
209. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, et al,. (2006). Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2: 434-441. (Pubitemid 44114922)
210. Sattler K, Levkau B, (2009). Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 82: 201-211.
211. Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler MH, et al,. (2010). Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 105: 821-832.
212. Sauer B, Vogler R, von Wenckstern H, Fujii M, Anzano MB, Glick AB, et al,. (2004). Involvement of Smad signaling in sphingosine 1-phosphate-mediated biological responses of keratinocytes. J Biol Chem 279: 38471-38479. (Pubitemid 39295999)
213. Schaphorst KL, Chiang E, Jacobs KN, Zaiman A, Natarajan V, Wigley F, et al,. (2003). Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol 285: L258-L267. (Pubitemid 36736489)
214. Sensken SC, Staubert C, Keul P, Levkau B, Schoneberg T, Graler MH, (2008). Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate. Cell Signal 20: 1125-1133.
215. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM, (2010). Prolonged S1P1 agonist exposure exacerbates vascular leak, fibrosis, and mortality after lung injury. J Respir Cell Mol Biol 43: 662-673.
216. Sheikine Y, Hansson GK, (2004). Chemokines and atherosclerosis. Ann Med 36: 98-118. (Pubitemid 38510016)
217. Shimamura K, Takashiro Y, Akiyama N, Hirabayashi T, Murayama T, (2004). Expression of adhesion molecules by sphingosine 1-phosphate and histamine in endothelial cells. Eur J Pharmacol 486: 141-150. (Pubitemid 38224525)
218. Shimizu H, Takahashi M, Kaneko T, Murakami T, Hakamata Y, Kudou S, et al,. (2005). KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 111: 222-229. (Pubitemid 40139735)
219. Shimizu T, Nakazawa T, Cho A, Dastvan F, Shilling D, Daum G, et al,. (2007). Sphingosine 1-phosphate receptor 2 negatively regulates neointimal formation in mouse arteries. Circ Res 101: 995-1000. (Pubitemid 350110273)
220. Singer II, Tian M, Wickham LA, Lin J, Matheravidathu SS, Forrest MJ, et al,. (2005). Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J Immunol 175: 7151-7161. (Pubitemid 41713408)
221. Singleton PA, Dudek SM, Chiang ET, Garcia JG, (2005). Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 19: 1646-1656. (Pubitemid 41429522)
222. Singleton PA, Dudek SM, Ma SF, Garcia JG, (2006). Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 281: 34381-34393. (Pubitemid 46036646)
223. Skoura A, Hla T, (2009). Regulation of vascular physiology and pathology by the S1P2 receptor subtype. Cardiovasc Res 82: 221-228.
224. Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, Hla T, (2007). Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest 117: 2506-2516. (Pubitemid 47494352)
225. Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, et al,. (2011). Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 31: 81-85.
226. Song J, Matsuda C, Kai Y, Nishida T, Nakajima K, Mizushima T, et al,. (2008). A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther 324: 276-283. (Pubitemid 350294170)
227. Spiegel S, Milstien S, (2003a). Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem Soc Trans 31 (Pt 6): 1216-1219. (Pubitemid 38030942)
228. Spiegel S, Milstien S, (2003b). Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev 4: 397-407. (Pubitemid 36565571)
229. Sun HY, Wei SP, Xu RC, Xu PX, Zhang WC, (2010). Sphingosine-1-phosphate induces human endothelial VEGF and MMP-2 production via transcription factor ZNF580: novel insights into angiogenesis. Biochem Biophys Res Commun 395: 361-366.
230. Sun X, Shikata Y, Wang L, Ohmori K, Watanabe N, Wada J, et al,. (2009). Enhanced interaction between focal adhesion and adherens junction proteins: involvement in sphingosine 1-phosphate-induced endothelial barrier enhancement. Microvasc Res 77: 304-313.
231. Suzuki C, Takahashi M, Morimoto H, Izawa A, Ise H, Fujishiro J, et al,. (2006). Efficacy of mycophenolic acid combined with KRP-203, a novel immunomodulator, in a rat heart transplantation model. J Heart Lung Transplant 25: 302-309. (Pubitemid 43290661)
232. Szczepaniak WS, Pitt BR, McVerry BJ, (2010). S1P2 receptor-dependent Rho-kinase activation mediates vasoconstriction in the murine pulmonary circulation induced by sphingosine 1-phosphate. Am J Physiol Lung Cell Mol Physiol 299: L137-L145.
233. Takabe K, Paugh SW, Milstien S, Spiegel S, (2008). 'Inside-out' signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60: 181-195. (Pubitemid 351962008)
234. Takashima S, Sugimoto N, Takuwa N, Okamoto Y, Yoshioka K, Takamura M, et al,. (2008). G12/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase. Cardiovasc Res 79: 689-697.
235. Takeya H, Gabazza EC, Aoki S, Ueno H, Suzuki K, (2003). Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood 102: 1693-1700. (Pubitemid 37022562)
236. Takuwa Y, Okamoto Y, Yoshioka K, Takuwa N, (2008). Sphingosine-1- phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta 1781: 483-488.
237. Tamama K, Kon J, Sato K, Tomura H, Kuwabara A, Kimura T, et al,. (2001). Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. Biochem J 353 (Pt 1): 139-146. (Pubitemid 32094608)
238. Tamama K, Tomura H, Sato K, Malchinkhuu E, Damirin A, Kimura T, et al,. (2005). High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 178: 19-23. (Pubitemid 39600811)
239. Tanimoto T, Jin ZG, Berk BC, (2002). Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem 277: 42997-43001. (Pubitemid 35285679)
240. Tanimoto T, Lungu AO, Berk BC, (2004). Sphingosine 1-phosphate transactivates the platelet-derived growth factor beta receptor and epidermal growth factor receptor in vascular smooth muscle cells. Circ Res 94: 1050-1058. (Pubitemid 38579699)
241. Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, et al,. (2010). High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 298: H1022-H1028.
242. Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, et al,. (2006). Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 82: 1689-1697. (Pubitemid 46035653)
243. Thangada S, Khanna KM, Blaho VA, Oo ML, Im DS, Guo C, et al,. (2010). Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med 207: 1475-1483.
244. Tigyi G, Valentine WJ, Kiss GN, Liu J, Lu X, Sun C, et al,. (2010). FTY720 S-ene-phosphonate is a novel pan-antagonist of the S1P receptors that inhibits lymphocyte egress. FASEB J 24 (1-MeetingAbstracts): lb100.
245. Tolle M, Levkau B, Keul P, Brinkmann V, Giebing G, Schonfelder G, et al,. (2005). Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res 96: 913-920. (Pubitemid 40604976)
246. Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, et al,. (2008). HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 28: 1542-1548.
247. Tolle M, Schuchardt M, van der Giet M, (2010). Relevance of sphingolipids in the pleiotropic protective effects of high-density lipoproteins. Curr Pharm Des 16: 1468-1479.
248. Usui S, Sugimoto N, Takuwa N, Sakagami S, Takata S, Kaneko S, et al,. (2004). Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J Biol Chem 279: 12300-12311. (Pubitemid 38445796)
249. Valentine WJ, Kiss GN, Liu J, Shuyu E, Gotoh M, Murakami-Murofushi K, et al,. (2010). (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. Cell Signal 22: 1543-1553.
250. Van Brocklyn JR, Lee MJ, Menzeleev R, Olivera A, Edsall L, Cuvillier O, et al,. (1998). Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol 142: 229-240. (Pubitemid 28341153)
251. Van Brocklyn JR, Tu Z, Edsall LC, Schmidt RR, Spiegel S, (1999). Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218. J Biol Chem 274: 4626-4632.
252. Van Brocklyn JR, Behbahani B, Lee NH, (2002). Homodimerization and heterodimerization of S1P/EDG sphingosine-1-phosphate receptors. Biochim Biophys Acta 1582: 89-93. (Pubitemid 34634115)
253. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, et al,. (2008). Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 102: 669-676. (Pubitemid 351457860)
254. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al,. (2006). Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9: 225-238. (Pubitemid 43357948)
255. Waeber C, Blondeau N, Salomone S, (2004). Vascular sphingosine-1- phosphate S1P1 and S1P3 receptors. Drug News Perspect 17: 365-382. (Pubitemid 39295641)
256. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, et al,. (2007). Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol 27: 275-282. (Pubitemid 46143040)
257. Wamhoff BR, Lynch KR, Macdonald TL, Owens GK, (2008). Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 28: 1454-1461.
258. Wang F, Okamoto Y, Inoki I, Yoshioka K, Du W, Qi X, et al,. (2010). Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. J Clin Invest 120: 3979-3995.
259. Wang L, Dudek SM, (2009). Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 77: 39-45.
260. Waters C, Sambi B, Kong KC, Thompson D, Pitson SM, Pyne S, et al,. (2003). Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGF beta receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle cells. J Biol Chem 278: 6282-6290. (Pubitemid 36800885)
261. Watterson KR, Lanning DA, Diegelmann RF, Spiegel S, (2007). Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen 15: 607-616. (Pubitemid 47495881)
262. Weber C, Zernecke A, Libby P, (2008). The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8: 802-815.
263. Weis T, Volker W, Holtwick R, Al Chahaf M, Schmidt A, (2010). Sphingosine 1-phosphate (S1P) induces expression of E-selectin and adhesion of monocytes via intracellular signalling pathways in vascular endothelial cells. Eur J Cell Biol 89: 733-741.
264. Wendler CC, Rivkees SA, (2006). Sphingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development. Dev Biol 291: 264-277.
265. Whetzel AM, Bolick DT, Srinivasan S, Macdonald TL, Morris MA, Ley K, et al,. (2006). Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 99: 731-739. (Pubitemid 44498306)
266. Wolf AM, Eller K, Zeiser R, Durr C, Gerlach UV, Sixt M, et al,. (2009). The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol 183: 3751-3760.
267. Wong L, Tan SSL, Lam Y, Melendez AJ, (2009). Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem 52: 3618-3626.
268. Wu WT, Chen CN, Lin CI, Chen JH, Lee H, (2005). Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 146: 3387-3400. (Pubitemid 41058111)
269. Wymann MP, Schneiter R, (2008). Lipid signalling in disease. Nat Rev 9: 162-176. (Pubitemid 351158917)
270. Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, et al,. (1998). Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 95: 14196-14201. (Pubitemid 28549344)
271. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR, (1999a). High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 274: 33143-33147. (Pubitemid 129535357)
272. Xia P, Wang L, Gamble JR, Vadas MA, (1999b). Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial
273. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, et al,. (2004a). Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J Biol Chem 279: 35255-35262. (Pubitemid 39100522)
274. Xin C, Ren S, Pfeilschifter J, Huwiler A, (2004b). Heterologous desensitization of the sphingosine-1-phosphate receptors by purinoceptor activation in renal mesangial cells. Br J Pharmacol 143: 581-589. (Pubitemid 39524275)
275. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A, (2007). FTY720 suppresses interleukin-1beta-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism. Br J Pharmacol 150: 943-950. (Pubitemid 46536630)
276. Xu CB, Zhang Y, Stenman E, Edvinsson L, (2002). D-erythro-N,N- dimethylsphingosine inhibits bFGF-induced proliferation of cerebral, aortic and coronary smooth muscle cells. Atherosclerosis 164: 237-243. (Pubitemid 35223072)
277. Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, et al,. (2005). FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 65: 7478-7484. (Pubitemid 41161283)
278. Yatomi Y, Yamamura S, Ruan F, Igarashi Y, (1997). Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid. J Biol Chem 272: 5291-5297. (Pubitemid 27090092)
279. Yonesu K, Kawase Y, Inoue T, Takagi N, Tsuchida J, Takuwa Y, et al,. (2009). Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog. Biochem Pharmacol 77: 1011-1020.
280. Yonesu K, Nakamura T, Mizuno Y, Suzuki C, Nagayama T, Satoh S, et al,. (2010). A novel sphingosine-1-phosphate receptor 1 antagonist prevents the proliferation and relaxation of vascular endothelial cells by sphingosine-1-phosphate. Biol Pharm Bull 33: 1500-1505.
281. Young N, Van Brocklyn JR, (2006). Signal transduction of sphingosine-1-phosphate G protein-coupled receptors. ScientificWorldJournal 6: 946-966. (Pubitemid 44252720)
282. Zachariah MA, Cyster JG, (2010). Neural crest-derived pericytes promote egress of mature thymocytes at the corticomedullary junction. Science 328: 1129-1135.
283. Zhang B, Tomura H, Kuwabara A, Kimura T, Miura S, Noda K, et al,. (2005). Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 178: 199-205. (Pubitemid 39600834)
284. Zhang G, Xu S, Qian Y, He P, (2010). Sphingosine 1-phosphate (S1P) prevents permeability increases via activation of endothelial S1P receptor 1 in rat venules. Am J Physiol Heart Circ Physiol 299: H1494-H1504.